February 16th, 2009
Lung cancer rates, which have fallen by a fifth over the last 20 years, are set to continue heading downwards, a study has shown.
Cancer Research UK cites a fall in smokers due to recent bans on tobacco advertising and smoking in public places as driving down the overall rate of lung cancer from 50 to 40 cases per 100,000 in the UK by 2024.
February 16th, 2009
FT. LAUDERDALE, FL–A south Florida man who once made his living selling cigarettes now hopes he lives long enough for his lawsuit against the tobacco industry to make it to trial.
Alan Landers was the actor who appeared as the Winston Man in print and billboard advertising across America in the 1960′s and 70′s.
A life long smoker, he was diagnosed with his first bout of lung cancer in 1987. In 1992, doctors found cancer in his other lung. Multiple surgeries, radiation and chemotherapy treatments followed, some with devastating side effects.
February 15th, 2009
Heart disease and cancer continue to be the leading and second leading causes of death, together accounting for almost one-half of all deaths, according to the National Center for Health Statistics. This year’s report on cancer statistics in the United States reveals that the types of cancers occurring most often among the general population are prostate cancer, female breast cancer and lung cancer.
February 15th, 2009
THE Court of Appeals (CA) has affirmed its decision ordering the lower court to hear and decide on the complaint for damages filed by a lung-cancer patient against Philip Morris Philippines Manufacturing Inc.
In a three-page resolution penned by Associate Justice Fernanda Lampas-Peralta, the CA’s Former Seventh Division dismissed Philip Morris’s motion for reconsideration seeking the reversal of its September 22, 2008, ruling for lack of merit.
February 14th, 2009
Green tea has been drunk for thousands of years in China and is recognised for its healthy properties. More recently, the active components have been identified as polyphenols, a set of compounds that are natural antioxidants and include the catechin family. During modern studies of the protective effects of green tea, it has been shown to be effective against several types of cancer, including lung cancer, the leading cancer killer of the Western world.
February 13th, 2009
Lung cancer is a major public health issue worldwide because of its high incidence rates in virtually all countries and poor overall survival (OS) of only 15% at 5 years.1 More than 80% of all lung tumors are non–small cell lung cancer (NSCLC). Unfortunately, only one-third of NSCLC patients present with early-stage cancers that are amenable to surgical treatment with curative intent. Sadly, even among this group, 30% to 70% of patients will recur and die of their disease.2
February 13th, 2009
Two doctors here have launched a Lung Cancer Clinic at Spokane-based Rockwood Clinic PS to streamline diagnosis and care for lung cancer patients.
The physicians, Dr. Jay Wittenkeller, a medical oncologist who practices at Rockwood Clinic, and Dr. Gregory Loewen, a pulmonologist at Spokane Respiratory Consultants PS, have collaborated with Rockwood to start the clinic, which operates for a half-day every other week at Rockwood’s downtown Cancer Treatment Center, at 910 W. Fifth.
February 12th, 2009
THURSDAY, Feb. 12 (HealthDay News) — A 21-day regimen of irinotecan and carboplatin is effective and well-tolerated in treating extensive and relapsed small-cell lung cancer, according to the results of a study published online Feb. 9 in the Journal of Clinical Oncology.
February 12th, 2009
Novelos Therapeutics has agreed to license and commercialize its lung-cancer drug in a deal that could result in up to $95 million in payments to the cash-strapped pharmaceutical company.
The timing couldn’t be better for the Newton, Mass.-based drug maker, as analysts predicted it would run out of cash by the end of this month.
February 12th, 2009
A small London company is a step closer to developing more effective treatments for many people afflicted with colon and lung cancer.
. (COTI) has announced it will start animal testing of a new treatment — a compound called COTI-2 –over the next few months before moving on to human clinical trials.